389 related articles for article (PubMed ID: 30844812)
1. Serotonergic Regulation and Cognition after Stroke: The Role of Antidepressant Treatment and Genetic Variation.
Damsbo AG; Kraglund KL; Buttenschøn HN; Johnsen SP; Andersen G; Mortensen JK
Cerebrovasc Dis; 2019; 47(1-2):72-79. PubMed ID: 30844812
[TBL] [Abstract][Full Text] [Related]
2. Common selective serotonin reuptake inhibitor side effects in older adults associated with genetic polymorphisms in the serotonin transporter and receptors: data from a randomized controlled trial.
Garfield LD; Dixon D; Nowotny P; Lotrich FE; Pollock BG; Kristjansson SD; Doré PM; Lenze EJ
Am J Geriatr Psychiatry; 2014 Oct; 22(10):971-9. PubMed ID: 24021217
[TBL] [Abstract][Full Text] [Related]
3. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression.
Hu XZ; Rush AJ; Charney D; Wilson AF; Sorant AJ; Papanicolaou GJ; Fava M; Trivedi MH; Wisniewski SR; Laje G; Paddock S; McMahon FJ; Manji H; Lipsky RH
Arch Gen Psychiatry; 2007 Jul; 64(7):783-92. PubMed ID: 17606812
[TBL] [Abstract][Full Text] [Related]
4. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
Lenox-Smith AJ; Jiang Q
Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
[TBL] [Abstract][Full Text] [Related]
5. SLC6A4 variation and citalopram response.
Mrazek DA; Rush AJ; Biernacka JM; O'Kane DJ; Cunningham JM; Wieben ED; Schaid DJ; Drews MS; Courson VL; Snyder KA; Black JL; Weinshilboum RM
Am J Med Genet B Neuropsychiatr Genet; 2009 Apr; 150B(3):341-51. PubMed ID: 18618621
[TBL] [Abstract][Full Text] [Related]
6. Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms.
Dombrovski AY; Mulsant BH; Ferrell RE; Lotrich FE; Rosen JI; Wallace M; Houck PR; Mazumdar S; Pollock BG
Int Clin Psychopharmacol; 2010 Jan; 25(1):37-45. PubMed ID: 19996755
[TBL] [Abstract][Full Text] [Related]
7. Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults.
Lenze EJ; Goate AM; Nowotny P; Dixon D; Shi P; Bies RR; Lotrich FK; Rollman BL; Shear MK; Thompson PA; Andreescu C; Pollock BG
J Clin Psychopharmacol; 2010 Dec; 30(6):672-7. PubMed ID: 21105279
[TBL] [Abstract][Full Text] [Related]
8. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample.
Kraft JB; Peters EJ; Slager SL; Jenkins GD; Reinalda MS; McGrath PJ; Hamilton SP
Biol Psychiatry; 2007 Mar; 61(6):734-42. PubMed ID: 17123473
[TBL] [Abstract][Full Text] [Related]
9. Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder.
Ruhé HG; Ooteman W; Booij J; Michel MC; Moeton M; Baas F; Schene AH
Pharmacogenet Genomics; 2009 Jan; 19(1):67-76. PubMed ID: 18987562
[TBL] [Abstract][Full Text] [Related]
10. Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action.
Zhong H; Haddjeri N; Sánchez C
Psychopharmacology (Berl); 2012 Jan; 219(1):1-13. PubMed ID: 21901317
[TBL] [Abstract][Full Text] [Related]
11. Evidence for a combined genetic effect of the 5-HT(1A) receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram.
Arias B; Catalán R; Gastó C; Gutiérrez B; Fañanás L
J Psychopharmacol; 2005 Mar; 19(2):166-72. PubMed ID: 15728438
[TBL] [Abstract][Full Text] [Related]
12. Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors.
Smits K; Smits L; Peeters F; Schouten J; Janssen R; Smeets H; van Os J; Prins M
Int Clin Psychopharmacol; 2007 May; 22(3):137-43. PubMed ID: 17414739
[TBL] [Abstract][Full Text] [Related]
13. Validation of [(123)I]beta-CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram.
de Win MM; Habraken JB; Reneman L; van den Brink W; den Heeten GJ; Booij J
Neuropsychopharmacology; 2005 May; 30(5):996-1005. PubMed ID: 15770240
[TBL] [Abstract][Full Text] [Related]
14. Is selectivity for serotonin uptake associated with a reduced emergence of manic episodes in depressed patients?
Barak Y; Kimhi R; Weizman R
Int Clin Psychopharmacol; 2000 Jan; 15(1):53-6. PubMed ID: 10836288
[TBL] [Abstract][Full Text] [Related]
15. The effects of the dopamine and serotonin transporter polymorphisms on clinical features and treatment response in geriatric depression: a pilot study.
Lavretsky H; Siddarth P; Kumar A; Reynolds CF
Int J Geriatr Psychiatry; 2008 Jan; 23(1):55-9. PubMed ID: 17621383
[TBL] [Abstract][Full Text] [Related]
16. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.
Clayton AH; Croft HA; Horrigan JP; Wightman DS; Krishen A; Richard NE; Modell JG
J Clin Psychiatry; 2006 May; 67(5):736-46. PubMed ID: 16841623
[TBL] [Abstract][Full Text] [Related]
17. Serotonin transporter 5-HTTLPR polymorphism and response to citalopram in terminally ill cancer patients: report of twenty-one cases.
Capozzo MA; Schillani G; Aguglia E; De Vanna M; Grassi L; Conte MA; Giraldi T
Tumori; 2009; 95(4):479-83. PubMed ID: 19856660
[TBL] [Abstract][Full Text] [Related]
18. Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders.
Kronenberg S; Apter A; Brent D; Schirman S; Melhem N; Pick N; Gothelf D; Carmel M; Frisch A; Weizman A
J Child Adolesc Psychopharmacol; 2007 Dec; 17(6):741-50. PubMed ID: 18315446
[TBL] [Abstract][Full Text] [Related]
19. The effect of selective serotonin reuptake inhibitors in healthy first-degree relatives of patients with major depressive disorder - an experimental medicine blinded controlled trial.
Knorr UB
Dan Med J; 2012 Apr; 59(4):B4426. PubMed ID: 22459724
[TBL] [Abstract][Full Text] [Related]
20. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care.
Lepola UM; Loft H; Reines EH
Int Clin Psychopharmacol; 2003 Jul; 18(4):211-7. PubMed ID: 12817155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
